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See related article on page 804.doi:10.1016/j.jtcvs.2004.08.046The philosophy that radical surgical resection of all malignant tissuecan be curative, even for advanced tumors, has widely influenced thetherapeutic thinking of surgeons in the early days and, to somedegree, still remains alive in many surgeons at present. In view ofour modern understanding of tumor biology in general and the grimprognosis of bronchial cancer in particular, the value of such ex-
tended operations must, however, seriously be questioned. In this issue of the
Journal, the article “Surgical resection for lung cancer with infiltration of the
thoracic aorta” by Ohta and colleagues1 again raises the question of whether surgical
intervention for advanced tumors, particularly for T4 tumors with infiltration of the
large vessels, can inhere oncologic benefit for our patients or rather must be seen as
an extreme operation, which is more of technical attractiveness to the surgeon than
of therapeutic value for the patient.
The question can be approached from different sides. Above all, one has to ask
for the statistical proof of the survival advantage for patients treated for locally
advanced T3/T4 bronchial cancer. One must accept that this advantage can hardly
be demonstrated from the existing literature. All documented experience about
surgical intervention for T3/T4 non–small cell lung cancer has been collected in
rather small series only,2-4 which is in clear contrast to the large number of patients
that usually is necessary to demonstrate treatment benefit of only moderate extent.
For example, in a recently published prospective randomized study by the Interna-
tional Adjuvant Lung Cancer Trial Collaborative Group,5 more then 1800 patients
were necessary to document a 4.1% survival benefit after 5 years in a group of
patients who received adjuvant chemotherapy for non–small cell lung cancer stages
I, II, and III. Furthermore, results of treatment of T3/T4 tumors usually are obtained
over considerably long periods of time, and there is uniform lack of a well-matched
control group that would allow serious statistical comparison. Therefore, our in-
ability to provide clear statistical evidence for treatment of such rather rare tumor
situations must not be regarded as indicative that the proposed therapy necessarily
lacks benefit at all. Localized tumors with infiltration of the thoracic aorta represent
an even more rare entity than the already small category of other advanced tumors
with infiltration of the vertebral column,6 the carina,7 or the apex of the chest.8 At
least for the latter 2 situations, accepted criteria for surgical treatment do exist, and
survival benefit from combined treatment modalities, including surgical interven-
tion, is anticipated, even without existing statistical evidence. The problem is,
however, not infrequent in modern medicine, where the challenge to deal with more
and more difficult and complex situations clearly implies that we are increasingly
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sufficiently high rate to allow meaningful statistical analy-
sis.
But do we really lack all statistical feedback for the
selection of patients with advanced tumors for surgical
intervention? Certainly not, because it has repeatedly been
demonstrated in the surgical literature that the prognosis
after operations for T3/T4 tumors mainly depends on the N
stage.9 Whether one looks at results after combined resec-
tion of the lung and the chest wall10 or after resection of the
lung and the central airways,7 it uniformly turns out that
patients with N0 or minimal N1 disease do significantly
better after radical resection, a finding that clearly justifies
operative therapy in these patients. In view of these obser-
vations, one would be tempted to apply similar criteria for
operation of patients with localized tumors infiltrating the
aorta. In fact, this is precisely the message that comes out of
Dr Ohta’s article,1 in which patients with N0 disease had an
impressively high 70% five-year survival after radical sur-
gical intervention.
On the basis of these considerations, should we therefore
be allowed to routinely recommend such an aggressive
surgical treatment as combined resection of the lung and the
aorta represents for our patients? The answer clearly is no.
In addition to the oncologic aspects, operative treatment
of tumors with infiltration of the thoracic aorta differs from
treatment of other advanced tumors in the important aspect
of the need for cardiopulmonary bypass for resection.
This implies not only a clear increase in surgical com-
plexity but also implies increased perioperative risks as
well. In fact, the mortality and morbidity that is reported for
the operation is considerable,11,12 which again is demon-
strated in the current article by Ohta and colleagues,1 in
which results in this regard are not substantially better than
those reported in previous articles. Another reason for the
high morbidity and mortality of the operation is the limited
experience that can be built up with a procedure that is
performed on such a rare basis. Both the technical complex-
ity of the operation and its rare occurrence therefore suggest
centralization of the procedure to departments that express
profound and continuous interest in such problems and that
at the same time have a high degree of experience with both
cardiac and general thoracic surgical procedures.
Another important drawback of the use of cardiopulmo-
nary bypass is potential scattering of tumor cells by suction
of blood that is then returned to the circuit system.12 As a
consequence, this can be expected to result in generalization
of a thus far localized disease; to achieve prognostic im-
provements, the long-term outcome would be even more
dismal. Two technical variants exist to avoid such a spread
of tumor cells. One, which has also been applied in a few
patients of Dr Ohta’s series, represents the use of a passive
shunt. The other, a more sophisticated approach, is the use
728 The Journal of Thoracic and Cardiovascular Surgery ● Apriof a femoro-femoral heparinized extracorporeal membrane
oxygenation system for resection of the descending aorta,
which avoids the need for full anticoagulation of the patient
during the resection and therefore the need for return of
suctioned blood into the circuit.12
After the perception that only patients with N0 or min-
imal N1 disease will potentially have a benefit from the
complex resection, the issue of adequate staging becomes
important. This must be seen as an absolute prerequisite that
implies the use of invasive staging procedures, and any
detected N2 disease should automatically exclude the pa-
tient from surgical treatment. However, we must be aware
that the quality of our staging frequently is limited in cases
in which direct video endoscopic access to subcarinal lymph
nodes might be prohibited by the adjacent tumor itself.
What has to be discussed further is the role of neoadju-
vant chemotherapy in this particular setting. The feasibility
of neoadjuvant chemotherapy in the treatment of different
forms of T3 and T4 tumors has repeatedly been demonstrat-
ed,13 and it is highly valid for T4 tumors with infiltration of
the great vessels as well. However, of the 3 general goals of
neoadjuvant chemotherapy, which are downsizing of large
tumors, eradication of undetected micrometastasis, and
downstaging of preoperatively detected lymph node in-
volvement, only the first 2 are applicable for treatment of T4
tumors with aortic infiltration because any preoperatively
detected N2 disease should automatically exclude these
patients from further operations.
If we summarize these considerations, surgical resection
of T4 tumors with infiltration of the aorta can be offered
under very strict conditions. It should only be considered if,
the tumor is localized, after exclusion of N2 involvement
and after neoadjuvant chemotherapy. Excellent functional
status of selected patients is mandatory, and the operation
should be performed in a specialized institution.
The operative morbidity and mortality of the procedure
remains to be seen as the major concern and carefully has to
be balanced against the scarcely existing evidence of onco-
logic benefit for the patient. However, potential prognostic
benefit for combined resection of the lung and the aorta
should not be denied categorically simply on the basis of the
argument of limited statistical proof.
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